Updated results from the Phase 2 COLIBRI trial suggest that adding immunotherapy before and after standard chemoradiation can significantly improve outcomes for patients with locally advanced cervical cancer. After a median follow-up of about 40 months, the treatment achieved a 3-year progression-free survival rate of 83% and an overall survival rate of 90%. Patients with […]
Researchershave created the most detailed map to date of meningioma, the most common brain tumor in adults. The study found that the tumor’s surrounding environment, particularly immune cells known as myeloid cells, plays a major role in determining how the cancer grows, returns, and responds to treatment. Using advanced technologies such as single-cell sequencing and
New Cellular Atlas of Meningioma Reveals Immune Signatures Linked to Tumor Recurrence Read More »
Teclistamab (Tecvayli) combined with daratumumab has emerged as a strong second-line treatment option for patients with relapsed or refractory multiple myeloma, especially for those who relapse after frontline quadruplet therapy and are not candidates for CAR T-cell therapy. In the phase 3 MajesTEC-3 trial involving 587 patients, the combination significantly outperformed standard therapy. Median progression-free
Trastuzumab pamirtecan (T-Pam; BNT323/DB-1303), a HER2-targeting antibody-drug conjugate, showed promising results in patients with advanced or recurrent HER2-expressing endometrial cancer who had progressed after chemotherapy and immunotherapy. In a phase 2 study of 145 patients with a median follow-up of 13.2 months, the treatment achieved a median progression-free survival of 8.0 months and a median
Bulumtatug fuvedotin (9MW2821), a Nectin-4–targeting antibody-drug conjugate, showed promising activity in patients with recurrent or metastatic cervical cancer who had progressed after platinum-based chemotherapy.. In a phase 1/2 study of 53 patients, 73.6% experienced tumor shrinkage. The confirmed overall response rate was 32.08%, including one complete response and 16 partial responses. Disease control was achieved
Researchers reported validation of a liquid biopsy-based model that predicts overall survival in recurrent ovarian cancer. The model uses a combination of blood protein markers and clinical factors to improve patient risk stratification and guide future research. The analysis was based on data from the phase 3 ANITA/ENGOT-OV41/GEICO 69-O trial, testing an 8-variable model in
Liquid Biopsy Biomarker Model Improves Survival Prediction in Recurrent Ovarian Cancer Read More »
Results from the phase 3 PANKU-Breast02 trial showed that izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate targeting EGFR and HER3, significantly improved outcomes in patients with previously treated advanced or metastatic triple-negative breast cancer (TNBC). Among 418 patients, iza-bren reduced the risk of disease progression or death by 71%, achieving a median progression-free survival of
A new multi-omics study has identified three molecular subtypes of colorectal cancer (CRC), with one subtype, known as CS3, showing strong potential for predicting response to immunotherapy. Researchers analyzed genetic, epigenetic, and molecular data and found that CS3 tumors are highly mutated, genomically unstable, and rich in immune activity. Importantly, CS3 includes a subset of
New CRC Subtype Could Broaden Immunotherapy Eligibility Read More »
An expert discussion highlighted how treatment of desmoid tumors has changed in recent years. Because many of these rare soft-tissue tumors can remain stable or even shrink on their own, doctors now often recommend active monitoring rather than immediate surgery, which has a high risk of recurrence. However, patients with growing or symptomatic tumors usually
Nirogacestat Demonstrates Durable Benefits for Progressive Desmoid Tumors Read More »
A new analysis suggests that zanubrutinib may provide better outcomes than ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL). Researchers compared data from two separate Phase 3 clinical trials and adjusted for differences in patient characteristics to create a balanced comparison. The results showed that patients treated with zanubrutinib had a
Zanubrutinib Outperforms Ibrutinib in Indirect Comparison for First-Line CLL Treatment Read More »